Professor University of Minnesota Minneapolis, Minnesota, United States
It will be one piece of a larger, 2-hr symposium. Presentation 4
Early Development Strategies and challenges for antibody drug conjugates drug substance.
Speaker: Dennie Welch, Ph.D. Director, AbbVie
The flexibility, high reactivity and complexity of ADC programs are already stretching the industry in biopharma operations and supply chain. Moreover, the non-crystalline intermediate purification and isolation can be challenging. The material scarcity can also limit drug-linker optimization and and method development. Speaker will discuss how to overcome these challenges to select appropriate strategies of ADC purification and characterization to improve yields and drug-linker quality
Learning Objectives:
To better understand the flexibility, high reactivity and complexity of ADCs
TO learn the non-crystalline intermediate purification and isolation challenges
To discuss challenges to select appropriate strategies of ADC purification and characterization to improve yields and drug-linker quality
Role of excipient phase behavior on the stability of the active pharmaceutical ingredient
